-

NYSE American to Suspend Trading in Viveon Health Acquisition Corp. (VHAQ)

NEW YORK--(BUSINESS WIRE)--NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to suspend trading in the three securities enumerated below (“Securities”) of Viveon Health Acquisition Corp. (the “Company”) from NYSE American. The staff suspended trading in the Company’s Securities because the Listings Qualifications Panel (the “Panel”) of the Committee for Review of the Board of Directors of the Exchange (the “Committee”) had issued a decision in which it upheld the Exchange’s previously announced determination to delist the Company’s Securities.

Symbol

Description

VHAQ

Common Stock

VHAQU

Units

VHAQR

Rights

The Exchange previously announced on December 22, 2023 that it had commenced delisting proceedings with respect to the Company’s Securities that same day pursuant to Sections 119(b) and 119(f) of the NYSE American Company Guide because the Company failed to consummate a business combination (i) within 36 months of the effectiveness of its initial public offering registration statement, or (ii) such shorter period that the Company specified in its registration statement. The Company had the right to request a review of this delisting determination by the Panel.

The Company has a right to a review of the Panel’s decision to delist the Securities by the Committee by making a written request within 15 calendar days of the date of the Panel’s decision. The filing by the Exchange of an application with the Securities and Exchange Commission to delist the Securities is pending completion of all applicable procedures, including any appeal by the Company of the Panel’s decision.

Contacts

Company Contacts:
Rom Papadopoulos, M.D.
Chief Financial Officer
T (404) 861-5393
E rom@viveonhealth.com

NYSE Contact:
NYSE Communications
PublicRelations-NYSE@ice.com

NYSE Regulation


Release Versions

Contacts

Company Contacts:
Rom Papadopoulos, M.D.
Chief Financial Officer
T (404) 861-5393
E rom@viveonhealth.com

NYSE Contact:
NYSE Communications
PublicRelations-NYSE@ice.com

More News From NYSE Regulation

NYSE Group Consolidated Short Interest Report

NEW YORK--(BUSINESS WIRE)--NYSE today reported short interest as of the close of business on the settlement date of February 27, 2026. SETTLEMENT DATE EXCHANGE TOTAL CURRENT SHORT INTEREST TOTAL PREVIOUS SHORT INTEREST (Revised) NUMBER of SECURITIES with a SHORT POSITION NUMBER of SECURITIES with a POSITION >= 5,000 SHARES 02/27/2026 NYSE 16,947,364,681 16,735,266,868 2,872 2,619 02/27/2026 NYSE ARCA 2,323,474,800 2,314,632,970 2,560 1,792 02/27/2026 NYSE AMERICAN 892,896,103 928,802,671 309...

NYSE to Commence Delisting Proceedings Against Allurion Technologies, Inc. (ALUR)

NEW YORK--(BUSINESS WIRE)--The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the two securities enumerated below (“Securities”) of Allurion Technologies, Inc. (the “Company”) from the NYSE. NYSE Regulation reached its decision to commence proceedings to delist the Company’s Securities pursuant to Section 802.01B of the NYSE’s Listed Company Manual because the Company had fallen below the NYSE’s...

NYSE to Commence Delisting Proceedings Against Vicarious Surgical Inc. (RBOT)

NEW YORK--(BUSINESS WIRE)--The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the Class A common stock of Vicarious Surgical Inc. (the “Company”) — ticker symbol RBOT — from the NYSE. Trading in the Company’s Class A common stock will be suspended immediately. NYSE Regulation reached its decision to delist the Company’s Class A common stock pursuant to Section 802.01B of the NYSE’s Listed Compan...
Back to Newsroom